钠-葡萄糖共转运蛋白2抑制剂治疗2型糖尿病心肾并发症的研究进展

Abstract
Figure/Table
References
Related Citation (15)

[1]	Sun H,Saeedi P,KarurangaS,et al.IDF diabetes atlas:global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 [J]. Diabetes Res Clin Pract, 2021, 183:109119.
[2]	Haas A V,Mcdonnell M E.Pathogenesis of cardiovascular disease in diabetes[J]. Endocrinol Metab Clin North Am, 2018, 47(1):51-63.
[3]	American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes-2021[J]. Diabetes Care,2021,44(Suppl 1):S151-S167.
[4]	Verma S,McMurray J J V.SGLT2 inhibitors and mechanisms of cardiovascular benefit:a state-of-the-art review[J]. Diabetologia,2018,61(10):2108-2117
[5]	DeFronzo R A,Hompesch M,Kasichayanula S,et al.Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes[J]. Diabetes Care,2013,36(10):3169-3176.
[6]	Lopaschuk G D,Verma S.Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review[J]. JACC Basic Transl Sci,2020,5(6):632-644.
[7]	Kang A,Jardine M J. SGLT2 inhibitors may offer benefit beyond diabetes[J].Nat Rev Nephrol,2021,17,83-84.
[8]	FathiA,Vickneson K, Singh J S,et al.SGLT2-inhibitors; more than just glycosuria and diuresis[J].Heart Fail Rev,2021, 26,623-642.
[9]	Li D,Wu T,Wang T,et al.Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes:a systematic review and meta-analysis of randomized controlled trials[J]. Pharmacoepidemiol Drug Saf,2020, 29(5): 582-590.
[10]	Barnett A H, Mithal A, Manassie J,et al.Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease:a randomized,double-blind,placebo- controlled trial[J]. Lancet Diabetes Endocrinol,2014, 2(5): 369- 384.
[11]	Fadini G P,Bonora B M,Zatti G,et al.Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial[J]. Cardiovasc Diabetol,2017, 16(1): 42.
[12]	Rahman A, Hitomi H, Nishiyama A.Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure[J]. Hypertens Res,2017,40(6):535-540.
[13]	Benham J L, Booth J E, Sigal R J,et al.Systematic review and meta-analysis:SGLT2 inhibitors, blood pressure and cardiovascular outcomes[J].Int J Cardiol Heart Vasc,2021,33:100725.
[14]	Sa-Nguanmoo P,Tanajak P,Kerdphoo S,et al.SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats[J].Toxicol Appl Pharmacol,2017,333:43-50.
[15]	Wang H,Yang J,Chen X,et al.Effects of sodium-glucose cotransporter 2 inhibitor monotherapy on weight changes in patients with type 2 diabetes mellitus : abayesian network meta-analysis[J].Clin Ther,2019,41(2):322-334.
[16]	Brown E, Wilding J P H, Barber T M,et al.Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities[J]. Obes Rev,2019,20(6):816-828.
[17]	Jjhb A,Fd A,Jwsa B.A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors SGLT2is) on biomarkers of inflammation and oxidative stress[J]. Diabetes Res Clin Pract,2020,168(20):108368.
[18]	Nabrdalik-LeniakD,Nabrdalik K,Sedlaczek K,et al.Influence of SGLT2 inhibitor treatment on urine antioxidant status in type 2 diabetic patients: a pilot study[J]. Oxid Med Cell Longev,2021, 21:559-589.
[19]	Das N A,Carpenter A J,Belenchia A,et al.Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition[J]. Cell Signal,2020, 68:109506.
[20]	Ryousuke S,Cypress M W,Cooper T W,et al.Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells[J].Am J Physiol Renal Physiol,2020,318(1):F67-F75.
[21]	Yaribeygi H,Butler A E,Atkin S L,et al.Sodium-glucose co-transporter 2 inhibitors and inflammation in chronic kidney disease:possible molecular pathways[J]. J Cell Physiol,2018,234(1):223-230.
[22]	Onishi M,Yamano K,Sato M,et al.Molecular mechanisms and physiological functions of mitophagy[J]. EMBO J, 2021,40(2):e104705.
[23]	Jiang K,Xu Y,Wang D D,et al.Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis[J]. Protein Cell,2022,13(5):336-359.
[24]	Wang C Y,Chen C C,Lin M H,et al.TLR9 binding to beclin 1 and mitochondrial SIRT3 by a sodium-glucose co-transporter 2 inhibitor protects the heart from doxorubicin toxicity[J]. Biology (Basel),2020,9(11):369.
[25]	Lee Y H,Kim S H,Kang J M,et al.Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy[J]. Am J Physiol Renal, 2019, 317(4):767-780.
[26]	Bhatia D,Choi M E.Autophagy in kidney disease: advances and therapeutic potential[J].Prog Mol Biol Transl Sci,2020,172:107-133.
[27]	Packer M.Role of impaired nutrient and oxygen deprivation signaling and deficient autophagic flux in diabetic ckd development:implications for understanding the effects of sodium-glucose cotransporter 2-inhibitors[J].J Am Soc Nephrol,2020,31(5):907-919.
[28]	Ye C I,Shaw R M,Pitt G S,et al.Na+ channel function, regulation,structure,trafficking and sequestration[J]. J Physiology, 2015, 593(6):1347-1360.
[29]	BaartscheerA,Schumacher C A,WüstRob C I,et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits[J].Diabetologia,2017, 60(3):568-573.
[30]	Empagliflozin inhibits Na+/H+ exchanger activity in human atrial cardiomyocytes[J].ESC Heart Failure,2020, 7:4429-4437.
[31]	Philippaert K,KalyaanamoorthyS,Fatehi M,et al.The cardiac late sodium channel current is a molecular targetfor the sodium-glucose co-transporter2 inhibitorempagliflozin[J].Circulation,2021,143(22):2188-2204.
[32]	Pablo L,Brian Z,Paul S,et al.Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor[J].Diabetes Vasc Dis Res,2015, 12(2):101-110.
[33]	Julian M,Olivia W,Lücht C M,et al.Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes[J]. ESC Heart Failure,2018,5(4):642-648.
[34]	ChenL,Larocque L,Efe O,et al.Effect of dapagliflozin treatment on fluid and electrolyte balance in diabetic rats[J].Am J Med Sci,2016,352(5):517-523.
[35]	Karg M V,Bosch A,Kannenkeril D,et al.SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial[J].Cardiovasc Diabetol,2018,17(1):5.
[36]	Zelniker T A,Braunwald E.Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020,75(4):435-447.
[37]	Ceriello A,Genovese S,Mannucci E,et al.Understanding EMPA-REG outcome[J].Lancet Diabetes Endo,2015, 3(12):929-930.
[38]	Hattori Y.Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization[J].Heart Fail Rev,2020,25(3):403-408.
[39]	DeFronzo R A,Reeves W B,Awad A S.Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors[J].Nat Rev Nephrol,2021,17(5):319-334.
[40]	Bommel E,Raalte D.The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind red trial[J]. Erratum Kidney Int,2020, 97(1):202-212.
[41]	王燕磊,肖建中.钠-葡萄糖共转运蛋白2抑制剂的肾脏保护循证证据与潜在机制[J].中华糖尿病杂志, 2021,13(10):1008-1012.
[42]	Akifumi K,Yusuke N,Yasuka M,et al.Role of Uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis[J].Mediat Inflamm, 2016,20(16):1-15.
[43]	Goldberg A,Garcia A F,Sasai F,et al.Mini review:reappraisal of uric acid in chronic kidney disease[J]. Am J Nephrol,2021,52(10-11):837-844.
[44]	Huang F,Zhao Y,Wang Q,et al.Dapagliflozin attenuates renal tubulointerstitial fibrosis associated with type 1 diabetes by regulating STAT1/TGF-β1 signaling[J]. Front Endocrinol,2019,10:441.